# TempraMed Signs Exclusive Distribution Agreement with DayMed Qatar, Expanding Gulf Region Commercial Footprint

- Link: https://www.thailand-business-news.com/pr-news/tempramed-signs-exclusive-distribution-agreement-with-daymed-qatar-expanding-gulf-region-commercial-footprint
- Published: 2026-11-16T22:35:00+07:00
- Author: Media OutReach

#### _Approximately US$500,000 in potential purchases over the initial three-year term, based on VIVI Cap minimum volumes; agreement targets Qatar’s high-prevalence diabetes market through hospital and pharmacy channels_

**Highlights**

 *  Exclusive distribution arrangement in Qatar with an initial 36-month term, intended
   to support local registration, marketing, sale and distribution of TempraMed 
   products
 *  Minimum unit purchase commitment with first purchase order paid in full before
   shipment, represents approximately $US 500,000 potential sales, subject to regulatory
   clearance, continued compliance with the Distribution Agreement and fulfillment
   of applicable purchase commitments
 *  Qatar had an estimated 409,300 adults with diabetes in 2024 and 24.6% age-standardized
   adult diabetes prevalence, according to the International Diabetes Federation(
   IDF)
 *  DayMed brings nearly five years of local market experience and reports commercial
   relationships with hospitals and major pharmacy chains, supporting a focused 
   patient-access strategy

 Toronto, Canada – Newsfile Corp. – November 16, 2026 – **TempraMed Technologies
Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) **(“**TempraMed**” or the “**Company**“),
a medical-technology innovator transforming how temperature-sensitive medications
are stored and managed, is pleased to announce that it has entered into a definitive
exclusive distribution agreement dated November 7, 2026 (the “**Distribution Agreement**“)
with DayMed Trading (“**DayMed**” or the “**Distributor**“) for commercialization
of TempraMed’s medication temperature-protection products in the State of Qatar.

 Under the Distribution Agreement, with a three-year commercial opportunity of approximately
US$500,000, DAYMED will serve as TempraMed’s exclusive distributor in Qatar for 
the Company’s products. The initial focus is VIVI Cap™, TempraMed’s reusable, passive
temperature-protection solution for insulin pens with further expansion to include
VIVI Cap Smart™ and VIVI Med™ as potential products within the distribution framework.

 _“Our agreement with DayMed is another meaningful step in building a scalable international
distribution network through partners who understand their local healthcare systems,”
said _**Ron Nagar, Chief Executive Officer and Founder of TempraMed**_. “Qatar presents
a compelling combination of high diabetes prevalence, increasing attention to metabolic
health and a climate in which patients must take particular care to protect temperature-
sensitive medications during day-to-day life.”_

 _“The approximately half-million-dollar potential under the initial agreement is
an important commercial opportunity, but the strategic value goes beyond the contractual
purchase volumes,” _**added Nagar.**_ “DayMed’s relationships with hospitals and
pharmacy chains can help bring VIVI Cap closer to patients at the point of prescription
and dispensing. We believe this model can support long-term growth as TempraMed 
expands through healthcare and pharmacy channels across the Gulf region.”_

 **Qatar Market Opportunity for Medication Temperature Protection**

 According to the IDF Diabetes Atlas, approximately 409,300 adults aged 20–79 were
living with diabetes in Qatar in 2024, with an age-standardized diabetes prevalence
of 24.6%—among the highest rates globally. These estimates reflect the substantial
population potentially requiring long-term diabetes care, including patients prescribed
injectable insulin therapies. [1, 2]

 Obesity and related metabolic conditions reinforce the relevance of injectable-
therapy support. A peer-reviewed analysis of Qatar’s 2023 STEPwise Survey, published
in BMJ Open in October 2026, reported obesity among 37.8% of surveyed adults aged
18–69 and overweight among another 36.4%. While these figures do not measure GLP-
1 prescriptions or TempraMed’s directly addressable customer base, they provide 
independent context for the growing importance of metabolic health and treatment-
support solutions. [3]

 Qatar’s Government Communications Office describes the country’s summers as hot
and humid, with temperatures ranging from 25°C to 46°C. Such conditions make appropriate
handling of temperature-sensitive medicines particularly important during commuting,
travel, outdoor activities and transport from pharmacy to home. TempraMed’s solutions
are designed to provide practical thermal protection during permitted in-use conditions,
while users must continue to follow each medication manufacturer’s labeled storage
instructions. [4]

 **About DAYMED Qatar **

 DayMed Trading is a Qatar-based healthcare distributor with nearly five years of
local market experience. According to information provided by DayMed, its portfolio
includes medical devices, pharmaceuticals and children’s multivitamins, and the 
company works with hospitals and major pharmacy chains across Qatar. Through its
partnership with TempraMed, DayMed intends to introduce VIVI Cap to patients who
use insulin, combining local healthcare-channel experience with TempraMed’s patented
medication temperature-protection technology.

 **About TempraMed Technologies Ltd.**

 TempraMed Technologies Ltd. is a global medical-device company with a portfolio
of innovative, temperature-controlled medication-storage solutions. Founded with
the mission to safeguard the effectiveness of life-saving medications, TempraMed
develops patented, FDA-registered thermal-insulation devices that operate continuously
without batteries or external power. Its commercial product portfolio includes VIVI
Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™. TempraMed enables patients and 
healthcare providers to confidently manage temperature-sensitive medications anywhere,
anytime.

 Investors interested in learning more about TempraMed are encouraged to contact
the Company at: 
 [ir@tempramed.com](https://www.thailand-business-news.com/pr-news/ir@tempramed.com)
[www.tempramed.com](https://api.newsfilecorp.com/redirect/kXZAjFQOOp)

 **Contact:** 
 Julia Becker  Director & Capital Markets  T: +1 (604) 785-0850  
E: [julia@tempramed.com](https://www.thailand-business-news.com/pr-news/julia@tempramed.com)

 Media: 
 Brenda Zeitlin  Vice President, Marketing  E: [brenda@tempramed.com](https://www.thailand-business-news.com/pr-news/brenda@tempramed.com)

 **Independent Market Sources** 
 1. International Diabetes Federation (IDF), Qatar
country profile, Diabetes in Qatar (2024): 409,300 adults with diabetes. [https://idf.org/our-network/regions-and-members/middle-east-and-north-africa/members/qatar/](https://api.newsfilecorp.com/redirect/B5wkEi2BB5)
2. IDF Diabetes Atlas, Qatar country report: 2024 age-standardized diabetes prevalence
of 24.6% among adults aged 20–79. [https://diabetesatlas.org/data-by-location/country/qatar/](https://api.newsfilecorp.com/redirect/5WjN8U3oPr)
3. Al-Thani MH et al., “Prevalence, risk factors and comorbidities of overweight
and obesity among adults in Qatar: a cross-sectional analysis of the 2023 Stepwise
Survey,” BMJ Open, October 2026. [https://bmjopen.bmj.com/content/16/10/e110307](https://api.newsfilecorp.com/redirect/LqEnySpzOJ)
4. State of Qatar, Government Communications Office, “Facts about Qatar,” climate
information. [https://www.gco.gov.qa/en/state-of-qatar/facts-about-qatar/](https://api.newsfilecorp.com/redirect/oPZAQcaOEr)

 **Cautionary Statements** 
 THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND
DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR
HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

 This press release contains “forward-looking information” and “forward-looking 
statements” within the meaning of applicable Canadian securities legislation. Forward-
looking statements may be identified by words such as “anticipate,” “believe,” “
expect,” “intend,” “may,” “plan,” “potential,” “should,” “strategy,” “will” and 
similar expressions, or statements concerning events or conditions that may occur
in the future.

 Forward-looking statements in this press release include, without limitation, statements
regarding the anticipated commercialization of TempraMed products in Qatar; the 
Distributor’s ability to obtain required regulatory clearance; the timing and completion
of product registration, importation and commercial launch activities; the fulfillment
of purchase commitments; the potential aggregate value of the Distribution Agreement;
consumer adoption of the products; market demand for temperature-protection solutions
for insulin, GLP-1 therapies, biologics and other injectable medications; the Distributor’s
capacity to develop hospital and pharmacy channels; anticipated minimum order volumes;
potential aggregate purchases and the actual product mix; future market demand; 
and the Company’s ability to expand across Qatar and the Gulf region. The approximately
US$500,000 value is an illustration based on the specified minimum annual quantities
and applicable VIVI Cap pricing tiers, not a guarantee of realized revenue.

 Forward-looking statements are based on the opinions, expectations and assumptions
of management as of the date of this press release, including assumptions regarding
receipt of required regulatory approvals, compliance by the Distributor with the
Distribution Agreement, market acceptance of TempraMed products, the Distributor’s
ability to commercialize the products in Qatar, and continued demand for medication
temperature-protection solutions.

 Forward-looking statements are subject to known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially from those 
expressed or implied, including regulatory approval and import requirements, the
possibility that purchase commitments may not be fulfilled, changes in market demand,
competitive developments, distributor performance, geopolitical risks, general economic
conditions, supply-chain limitations, and other risks described in the Company’s
public filings available on SEDAR+.

 Except as required by applicable securities laws, the Company undertakes no obligation
to update or revise publicly any forward-looking statements.

The issuer is solely responsible for the content of this announcement.

![](//track.media-outreach.com/index.php/WebView/501755/36955)

**Source** : [TempraMed Signs Exclusive Distribution Agreement with DayMed Qatar, Expanding Gulf Region Commercial Footprint](https://www.media-outreach.com/news/united-states/2026/11/16/501755/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://r2.thailand-business-news.com/wp-content/uploads/
2026/10/media-outreach-newswire-2025.svg)
